Medical Treatment for Gastroesophageal Reflux Disease (GERD) in Preterm Infants
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00131248|
Recruitment Status : Completed
First Posted : August 17, 2005
Results First Posted : January 15, 2014
Last Update Posted : January 15, 2014
- Study Details
- Tabular View
- Study Results
- How to Read a Study Record
Study Question: In premature infants with apnea and/or bradycardia attributed to gastroesophageal reflux disease (GERD), does treatment with medications (acid blockers and motility agents), compared to placebo, reduce the frequency of apnea and bradycardia?
Background: Many clinicians believe that apnea and bradycardia in preterm infants may be caused by gastroesophageal reflux (GER), however, studies have failed to demonstrate even a temporal association between episodes of GER and apnea. There have been no prospective randomized trials of treatment for GERD in preterm infants with apnea or other symptoms attributed to GER.
Methods: A randomized, cross-over study will be performed. This cross-over design will provide the patient's clinician with unbiased information about the patient's response to treatment. The clinician can use this information in deciding whether or not to continue treatment after the two-week study period.
|Condition or disease||Intervention/treatment||Phase|
|Gastroesophageal Reflux||Drug: Metaclopramide Drug: Ranitidine Drug: placebo||Phase 3|
Study Question: In premature infants with apnea and/or bradycardia attributed to GERD, does treatment with H2 blockers and prokinetic agents, compared to placebo, reduce the frequency of apnea and bradycardia?
Background: The incidence of gastroesophageal reflux (GER) has been reported in as many as 50% of healthy term infants and 63% of preterm infants. Anecdotal observations of apnea and bradycardia clustered around feedings or with an episode of vomiting have suggested to clinicians that apnea and bradycardia in preterm infants may be caused by reflux, however, studies have failed to demonstrate even a temporal association between episodes of GER and apnea. One retrospective study concluded that anti-reflux medications did not reduce the frequency of apnea in premature infants. There have been no prospective randomized trials of treatment for GERD in preterm infants with apnea or other symptoms attributed to GER. Despite the lack of evidence supporting a causal relationship between GER and respiratory problems in preterm infants and the lack of data regarding the efficacy or safety of the treatments for GERD, many clinicians continue to believe that GER causes respiratory symptoms in preterm infants and these infants are commonly treated with medications for GERD.
Specific aims: To determine whether medications for GER are effective in reducing respiratory symptoms attributed to GER.
Methods: A randomized, controlled masked cross-over study will be performed. The cross-over design will prevent evaluation of long-term outcomes but will increase the power to evaluate short-term outcomes by using the patient as his/her own control. This cross-over design will also provide the patient's clinician with unbiased information about the patient's response to treatment. The clinician can use this information in deciding whether or not to continue treatment after the two-week study period. This approach for making therapeutic decisions in individual patients has been described as an "N of 1" trial.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||18 participants|
|Intervention Model:||Crossover Assignment|
|Masking:||Double (Participant, Investigator)|
|Official Title:||Cross-over Trial of Medical Treatment for GERD in Preterm Infants|
|Study Start Date :||April 2004|
|Actual Primary Completion Date :||March 2008|
|Actual Study Completion Date :||March 2008|
Anti-reflux Medications, then Placebo (group 1)
3-day course of anti-reflux medications, followed by 7-day course placebo, followed by 4-day course anti-reflux medications.
All study medication administered via nipple or orogastric (OG) tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes.
Placebo, then Anti-reflux Medications
3-day course placebo, followed by 7-day course anti-reflux medication, followed by 4-day course placebo.
All study medication administered via nipple or OG tube. Metaclopramide (anti-reflux) given in 0.1mg/kg/dose q6hrs, 30min. prior to feedings. Ranitidine, 3mg/kg/dose, q12hrs. Saline placebo at same respective volumes.
- Bradycardia Episodes/Day [ Time Frame: 7 days ]
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
|Ages Eligible for Study:||1 Month to 6 Months (Child)|
|Sexes Eligible for Study:||All|
|Accepts Healthy Volunteers:||No|
- Premature infants < 37 weeks gestation at birth; currently less than 44 weeks postmenstrual age.
- Not currently receiving mechanical ventilation
- Clinical diagnosis of GER and apnea/bradycardia suspected by the clinicians to be related to the GER. (Supporting diagnostic test information, such as upper gastrointestinal series [UGI] studies and pH probes will be recorded but not required for study enrollment.)
- Attending physician plan to begin anti-reflux medications
- Infants may be included in the study if they are on continuous positive airway pressure (CPAP) or methylxanthines for treatment of apnea only if the clinicians are willing to maintain the same regimen for the two-week duration of the study.
- Stable feeding regimen
- History of congenital neurological defect
- Imminent discharge (within 2 weeks)
- Parent refusal
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00131248
|United States, Texas|
|Memorial Hermann Children's Hospital|
|Houston, Texas, United States, 77030|
|Principal Investigator:||Kathleen A Kennedy, MD, MPH||University of Texas|
|Responsible Party:||Kathleen Kennedy, Professor - Pediatrics-Neonatology, The University of Texas Health Science Center, Houston|
|Other Study ID Numbers:||
|First Posted:||August 17, 2005 Key Record Dates|
|Results First Posted:||January 15, 2014|
|Last Update Posted:||January 15, 2014|
|Last Verified:||December 2013|
Esophageal Motility Disorders
Digestive System Diseases
Ranitidine bismuth citrate
Peripheral Nervous System Agents
Physiological Effects of Drugs
Dopamine D2 Receptor Antagonists
Molecular Mechanisms of Pharmacological Action
Histamine H2 Antagonists